Moreover, combining AZ304 and the anti-EGFR monoclonal antibody Cetuximab resulted in significantly improved anti-tumour activity in colorectal cancer cells both in vitro and in vivo, independently of BRAF mutation status. The gene discussed is BRAF; the disease is colorectal cancer.